[Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?].
Mehnert
H
H
Forschergruppe Diabetes und III. Medizinische Abteilung Städtisches Krankenhaus Schwabing, München.
D000368:Aged; D000818:Animals; D001645:Biguanides / Q000008:administration & dosage / Q000627:therapeutic use*; D006224:Cricetinae; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005905:Glyburide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D051381:Rats; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
D001645:Biguanides; D013453:Sulfonylurea Compounds; D008687:Metformin; D005905:Glyburide
Sulfonylharnstoffe oder Biguanide in der Behandlung des Typ-II-Diabetes?